Last reviewed · How we verify
Fluoxetine+Olanzapine
Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects.
Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects. Used for Treatment-resistant depression, Bipolar I disorder depression.
At a glance
| Generic name | Fluoxetine+Olanzapine |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | SSRI + atypical antipsychotic combination |
| Target | Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. This combination leverages both monoamine systems to treat mood and psychotic symptoms simultaneously.
Approved indications
- Treatment-resistant depression
- Bipolar I disorder depression
Common side effects
- Weight gain
- Sedation
- Nausea
- Akathisia
- Sexual dysfunction
- Metabolic syndrome risk
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- National Pregnancy Registry for Psychiatric Medications
- Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (PHASE4)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression (PHASE3)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxetine+Olanzapine CI brief — competitive landscape report
- Fluoxetine+Olanzapine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI